Cargando…

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)

OBJECTIVE: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options. DESIGN: A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rathbone, John, Kaltenthaler, Eva, Richards, Anna, Tappenden, Paul, Bessey, Alice, Cantrell, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Renal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822313/ https://www.ncbi.nlm.nih.gov/pubmed/24189082 http://dx.doi.org/10.1136/bmjopen-2013-003573

Ejemplares similares

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
por: Dunn, Sarah, et al.
Publicado: (2022)

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017)

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)

Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)

L-Arginine/NO Pathway Is Altered in Children with Haemolytic-Uraemic Syndrome (HUS)
por: Kanzelmeyer, Nele Kirsten, et al.
Publicado: (2014)

Atypical Haemolytic Uraemic Syndrome Associated with Clostridium difficile Infection Successfully Treated with Eculizumab
por: Inglis, Joshua M., et al.
Publicado: (2018)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
por: Ariceta, Gema, et al.
Publicado: (2021)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
por: Walle, J Vande, et al.
Publicado: (2015)

10. Is Eculizumab a life-saving treatment for atypical Haemolytic Uraemic Syndrome in Lupus Pregnancy?
por: McGrath, Catherine, et al.
Publicado: (2017)

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019)

Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection
por: Fraga-Rodriguez, Gloria M, et al.
Publicado: (2017)

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective
por: ter Avest, Mendy, et al.
Publicado: (2022)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014)

Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovah’s Witness refusing blood products
por: Al-Shaghana, May, et al.
Publicado: (2017)

Successful Subsequent Pregnancy in a Woman Receiving Eculizumab for Pregnancy-Associated Atypical Haemolytic Uraemic Syndrome
por: Bateman, Samantha, et al.
Publicado: (2019)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab
por: Jeantet, Guillaume, et al.
Publicado: (2018)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018)

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
por: Ito, Shuichi, et al.
Publicado: (2022)

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis
por: Collett, James, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kvl84vs43275jruq7pqidckgp2